Two new trifunctional antibodies for the therapy of human malignant melanoma

International Journal of Cancer

Volumn 108, Issue 5, 2004, Pages 725-732

  Ruf, Peter ^a,d   Jäger, Michael ^a   Ellwart, Joachim ^b   Wosch, Susanne ^a   Kusterer, Elisabeth ^c   Lindhofer, Horst ^a,c  

^a TRION Pharma GmbH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c TRION Pharma GmbH   (Germany)

^d TRION Research GmbH   (Germany)

Author keywords

Immunotherapy; Malignant melanoma; Trifunctional antibodies

Indexed keywords

ANTIBODY; ANTIBODY TRBS02; ANTIBODY TRBS07; CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GANGLIOSIDE GD2; GANGLIOSIDE GD3; INTERLEUKIN 4; PROTEOGLYCAN; TRIFUNCTIONAL ANTIBODY; UNCLASSIFIED DRUG;

ACCESSORY CELL; ANTIGEN SPECIFICITY; ARTICLE; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOLYSIS; CYTOTOXICITY; HUMAN; HUMAN CELL; MELANOMA; MELANOMA CELL; MONOCYTE; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY SPECIFICITY; ANTIGENS, CD3; CELL LINE; CYTOKINES; GANGLIOSIDES; HUMANS; LYMPHOCYTE ACTIVATION; MELANOMA; PROTEOGLYCANS; T-LYMPHOCYTES; TUMOR CELLS, CULTURED;

EID: 0347915678     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11630     Document Type: Article

References (49)

1. Helmbach H, Rossmann E, Kern MA, Schadendorf D. Drug-resistance in human melanoma. Int J Cancer 2001;93:617-22.
2. Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996;14:7-17.
3. Kirkwood JM, Ibrahim JG, Sosman JA, Sondak VK, Agarwala SS, Ernstoff MS, Rao U. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/ QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 2001;19:2370-80.
4. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 2002;13:119-34.
5. Fanger MW, Segal DM, Wunderlich JR. Going both ways: bispecific antibodies and targeted cellular cytotoxicity. FASEB J 1990;4:2846-9.
6. Weiner LM, Clark JI, Ring DB, Alpaugh RK. Clinical development of 2B 1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. J Hematother 1995;4:453-6.
7. Heijnen IA, Rijks LJ, Schiel A, Stockmeyer B, van Ojik HH, Dechant M, et al. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies. J Immunol 1997;159:5629-39.
8. Valerius T, Stockmeyer B, van Spriel AB, Graziano RF, van den Herik-Oudijk IE, Repp R, Deo YM, Lund J, Kalden JR, Gramatzki M, van de Winkel JG. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy. Blood 1997;90:4485-92.
9. Zeidler R, Mysliwietz J, Csanady M, Walz A, Ziegler I, Schmitt B, et al. The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells. Br J Cancer 2000;83:261-6.
10. Zeidler R, Reisbach G, Wollenberg B, Lang S, Chaubal S, Schmitt B, Lindhofer H. Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing. J Immunol 1999;163:1246-52.
11. Lindhofer H, Menzel H, Gunther W, Hultner L, Thierfelder S. Bispecific antibodies target operationally tumor-specific antigens in two leukemia relapse models. Blood 1996;88:4651-8.
12. Riesenberg R, Buchner A, Pohla H, Lindhofer H. Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). J Histochem Cytochem 2001;49:911-7.
13. Ruf P, Lindhofer H. Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 2001;98:2526-34.
14. Herlyn M, Thurin J, Balaban G, Bennicelli JL, Herlyn D, Elder DE. et al. Characteristics of cultured human melanocytes isolated from different stages of tumor progression. Cancer Res 1985;45:5670-6.
15. Real FX, Houghton AN, Albino AP, Cordon-Cardo C, Melamed MR, Oettgen HF, Old LJ. Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. Cancer Res 1985;45:4401-11.
16. Thurin J, Thurin M, Kimoto Y, Herlyn M, Lubeck MD, Elder DE, et al. Monoclonal antibody-defined correlations in melanoma between levels of GD2 and GD3 antigens and antibody-mediated cytotoxicity. Cancer Res 1987;47:1229-33.
17. Martini F, Riondino S, Pignatelli P, Gazzaniga PP, Ferroni P, Lenti L. Involvement of GD3 in platelet activation: a novel association with Fcgamma receptor. Biochim Biophys Acta 2002;1583:297-304.
18. Svennerholm L, Bostrom K, Fredman P, Jungbjer B, Lekman A, Mansson JE, Rynmark BM. Gangliosides and allied glycosphingolipids in human peripheral nerve and spinal cord. Biochim Biophys Acta 1994;1214:115-23.
19. Riker AI, Kammula US, Panelli MC, Wang E, Ohnmacht GA, Steinberg SM, et al. Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. Int J Cancer 2000;86:818-26.
20. Clark M, Gilliland L, Waldmann H. Hybrid antibodies for therapy. Prog Allergy 1988;45:31-49.
21. Lindhofer H, Mocikat R, Steipe B, Thierfelder S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas: implications for a single-step purification of bispecific antibodies. J Immunol 1995;155:219-25.
22. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996;17:138-46,
23. +) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function. J Exp Med 2001;193:1295-302.
24. Cheresh DA, Honsik CJ, Staffileno LK, Jung G, Reisfeld RA. Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal anfibody-mediated tumor cytolysis. Proc Natl. Acad Sci USA 1985;82:5155-9.
25. Hellstrom I, Brankovan V, Hellstrom KE. Strong antitumor activities of IgG3 antibodies to a human melanoma-associated ganglioside. Proc Natl Acad Sci USA 1985;82:1499-502.
26. Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 anti-body. J Immunol 1990;144:1382-6.
27. Saleh MN, Khazaeli MB, Wheeler RH, Dropcho E, Liu T, Urist M, et al. Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma. Cancer Res 1992;52:4342-7.
28. Kirkwood JM, Mascari RA, Edington HD, Rabkin MS, Day RS, Whiteside TL, et al. Analysis of therapeutic and immunologic effects of R(24) anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer 2000;88:2693-702.
29. Albertini MR, Hank JA, Schiller JH, Khorsand M, Borchert AA, Gan J, et al. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin Cancer Res 1997;3:1277-88.
30. Becker JC, Pancook JD, Gillies SD, Mendelsohn J, Reisfeld RA. Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins. Proc Natl Acad Sci USA 1996;93:2702-7.
31. Hank JA, Surfus JE, Gan J, Jaeger P, Gillies SD, Reisfeld RA, Sondel PM. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2). Clin Cancer Res 1996;2:1951-9.
32. Loffler A, Kufer P, Lutterbuse R, Zettl F, Daniel PT, Schwenkenbecher JM, et al. A recombinant bispecific single-chain antibody, CD19 × CD3, induces rapid and high lymphoma-directed cytotoxicity, by unstimulated T lymphocytes. Blood 2000;95:2098-103.
33. Honeychurch J, Tutt AL, Valerius T, Heijnen IA, van de Winkel JG, Glennie MJ. Therapeutic efficacy of FcgammaRI/CD64-directed bispecific antibodies in B-cell lymphoma. Blood 2000;96:3544-52.
34. Weiner GJ, Hillstrom JR. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma. J Immunol 1991;147:4035-44.
35. Renner C, Jung W, Sahin U, Denfeld R, Pohl C, Trumper L, et al. Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science 1994;264:833-5.
36. Segal DM, Weiner GJ, Weiner LM. Bispecific antibodies in cancer therapy. Curr Opin Immunol 1999;11:558-62.
37. Daniel PT, Kroidl A, Kopp J, Sturm I, Moldenhauer G, Dorken B, Pezzutto A. Immunotherapy of B-cell lymphoma with CD3x 19 bispecific antibodies: costimulation via CD28 prevents "Veto" apoptosis of antibody-targeted cytotoxic T cells. Blood 1998;92:4750-7.
38. Daniel PT, Kroidl A, Cayeux S, Bargou R, Blankenstein T, Dorken B. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J Immunol 1997;159:3808-15.
39. Smans KA, Ingvarsson MB, Lindgren P, Canevari S, Walt H, Stigbrand T, et al. Bispecific antibody-mediated lysis of primary cultures of ovarian carcinoma cells using multiple target antigens. Int J Cancer 1999;83:270-7.
40. Bernhard H, Karbach J, Strittmatter W, Meyer zum Buschenfelde KH, Knuth A. Induction of tumor-cell lysis by bi-specific antibody recognizing ganglioside GD2 and T-cell antigen CD3. Int J Cancer 1993;55:465-70.
41. Berd D, Sato T, Cohn H, Maguire HC Jr, Mastrangelo MJ. Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int J Cancer 2001;94:531-9.
42. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat Med 1998;4:328-32.
43. Chapman PB, Morrisey D, Panageas KS, Williams L, Lewis JJ, Israel RJ, et al. Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin. Clin Cancer Res 2000;6:4658-62.
44. Livingston PO, Wong GY, Adluri S, Tao Y, Padavan M, Parente R, et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994;12:1036-44.
45. Keler T, Guyre PM, Vitale LA, Sundarapandiyan K, van de Winkel JG, Deo YM, Graziano RF. Targeting weak antigens to CD64 elicits potent humoral responses in human CD64 transgenic mice. J Immunol 2000;165:6738-42.
46. Snider DP, Kaubisch A, Segal DM. Enhanced antigen immunogenicity induced by bispecific antibodies. J Exp Med 1990;171:1957-63.
47. Mittelman A, Chen GZ, Wong GY, Liu C, Hirai S, Ferrone S. Human high molecular weight-melanoma associated antigen mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: modulation of the immunogenicity in patients with malignant melanoma. Clin Cancer Res 1995;1:705-13.
48. Thurin J, Thurin M, Herlyn M, Elder DE, Steplewski Z, Clark WH Jr, Koprowski H. GD2 ganglioside biosynthesis is a distinct biochemical event in human melanoma tumor progression. FEBS Lett 1986;208:17-22.
49. Houghton AN, Eisinger M, Albino AP, Cairncross JG, Old LJ. Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets. J Exp Med 1982;156:1755-66.